ALDH7A1 and chronic obstructive pulmonary disease: Roflumilast and Apremilast, which have now been approved for COPD and psoriatic arthritis, respectively, are recommended at doses which inhibit PDE activity by only 50% since any further increases were observed to induce nausea and emesis [320].